LEXX vs. APRE, ACST, SPRB, APM, LPCN, IPA, FBIO, ACXP, THTX, and EYEN
Should you be buying Lexaria Bioscience stock or one of its competitors? The main competitors of Lexaria Bioscience include Aprea Therapeutics (APRE), Acasti Pharma (ACST), Spruce Biosciences (SPRB), Aptorum Group (APM), Lipocine (LPCN), ImmunoPrecise Antibodies (IPA), Fortress Biotech (FBIO), Acurx Pharmaceuticals (ACXP), Theratechnologies (THTX), and Eyenovia (EYEN). These companies are all part of the "medical" sector.
Aprea Therapeutics (NASDAQ:APRE) and Lexaria Bioscience (NASDAQ:LEXX) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, analyst recommendations, community ranking, earnings, valuation and profitability.
34.2% of Aprea Therapeutics shares are held by institutional investors. Comparatively, 13.1% of Lexaria Bioscience shares are held by institutional investors. 20.9% of Aprea Therapeutics shares are held by company insiders. Comparatively, 7.6% of Lexaria Bioscience shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.
Lexaria Bioscience's return on equity of -65.58% beat Aprea Therapeutics' return on equity.
Aprea Therapeutics received 43 more outperform votes than Lexaria Bioscience when rated by MarketBeat users. However, 100.00% of users gave Lexaria Bioscience an outperform vote while only 51.72% of users gave Aprea Therapeutics an outperform vote.
Aprea Therapeutics has a beta of 1.03, indicating that its share price is 3% more volatile than the S&P 500. Comparatively, Lexaria Bioscience has a beta of 0.94, indicating that its share price is 6% less volatile than the S&P 500.
In the previous week, Aprea Therapeutics and Aprea Therapeutics both had 2 articles in the media. Aprea Therapeutics' average media sentiment score of 0.67 beat Lexaria Bioscience's score of 0.09 indicating that Lexaria Bioscience is being referred to more favorably in the news media.
Lexaria Bioscience has lower revenue, but higher earnings than Aprea Therapeutics. Lexaria Bioscience is trading at a lower price-to-earnings ratio than Aprea Therapeutics, indicating that it is currently the more affordable of the two stocks.
Aprea Therapeutics presently has a consensus price target of $15.50, suggesting a potential upside of 176.29%. Lexaria Bioscience has a consensus price target of $12.00, suggesting a potential upside of 433.33%. Given Aprea Therapeutics' higher probable upside, analysts clearly believe Lexaria Bioscience is more favorable than Aprea Therapeutics.
Summary
Aprea Therapeutics beats Lexaria Bioscience on 9 of the 15 factors compared between the two stocks.
Get Lexaria Bioscience News Delivered to You Automatically
Sign up to receive the latest news and ratings for LEXX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding LEXX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Lexaria Bioscience Competitors List
Related Companies and Tools
